- Home
- GSIW vs CMND Comparison
GSIW vs CMND Comparison
Compare GSIW & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | CMND |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 1.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GSIW | CMND |
|---|---|---|
| Price | $16.91 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 494.1K | 104.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.07 |
| 52 Week High | $36.90 | $3.25 |
Technical Indicators
Market Signals| Indicator | GSIW | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 30.36 |
| Support Level | $0.11 | $0.59 |
| Resistance Level | $36.90 | $1.27 |
| Average True Range (ATR) | 4.48 | 0.11 |
| MACD | -0.44 | 0.01 |
| Stochastic Oscillator | 30.48 | 16.50 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.